PDCD1 and chronic obstructive pulmonary disease: Additionally, PD-1 inhibitors seemed to cause an increased risk for IRPs (OR 2.5) compared to PD-L1 inhibitors [127], suggesting that drugs such as Atezolizumab or avelumab should be preferred in patients with COPD as a comorbidity.